Phase 2 study finds intranasal esketamine effective in treatment‐resistant depression | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Phase 2 study finds intranasal esketamine effective in treatment‐resistant depression

Publication year - 2018

Publication title -

the brown university psychopharmacology update

Language(s) - English

Resource type - Journals

eISSN - 1556-7532

pISSN - 1068-5308

DOI - 10.1002/pu.30309

Subject(s) - discontinuation , medicine , depression (economics) , antidepressant , placebo , treatment resistant depression , adverse effect , nasal administration , major depressive disorder , anesthesia , psychiatry , pharmacology , anxiety , alternative medicine , pathology , economics , macroeconomics , amygdala

Patients with treatment‐resistant depression who received intranasal esketamine as adjunctive therapy with an antidepressant experienced greater symptom improvement than patients receiving adjunctive placebo, a multiphase study with 67 participants has found. The antidepressant effect seen in the study was dose‐related, and adverse events led to study discontinuation in only a small number of participants. Study results were published online Dec. 27, 2017, in JAMA Psychiatry .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research